Drugs / TAVT-18
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04595513 | Sep 2020 → Dec 2022 | epilepsy, tuberous sclerosis | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAVT-18 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04595513 ↗ |
| Action | Inhibit | “TAVT-18 is a novel formulation of sirolimus, an mTOR inhibitor.” NCT04595513 ↗ |
| Route | Oral | “TAVT-18 administered orally twice/daily” NCT04595513 ↗ |